Related references
Note: Only part of the references are listed.Pancreatic duct cells as a source of VEGF in mice
Xiangwei Xiao et al.
DIABETOLOGIA (2014)
PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation
Shengquan Huang et al.
TUMOR BIOLOGY (2014)
Targeting SMAD3 for inhibiting prostate cancer metastasis
Qing Xia et al.
TUMOR BIOLOGY (2014)
The Changing Natural History of Metastatic Prostate Cancer
Ajjai Alva et al.
CANCER JOURNAL (2013)
New Strategies in Prostate Cancer: Translating Genomics into the Clinic
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Pathways: Adiponectin and Leptin Signaling in Cancer
Michael N. VanSaun
CLINICAL CANCER RESEARCH (2013)
Obesity and Prostate Cancer: Weighing the Evidence
Emma H. Allott et al.
EUROPEAN UROLOGY (2013)
Hypoglycemia Reduces Vascular Endothelial Growth Factor A Production by Pancreatic Beta Cells as a Regulator of Beta Cell Mass
Xiangwei Xiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
PROSTATE CANCER The androgen receptor remains front and centre
Philip J. Saylor
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Cells of origin for cancer: an updated view from prostate cancer
L. Xin
ONCOGENE (2013)
Adiponectin, an Anti-Carcinogenic Hormone? a Systematic Review on Breast, Colorectal, Liver and Prostate Cancer
S. Perrier et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Targeting angiogenesis for the treatment of prostate cancer
Emmanuel S. Antonarakis et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Angiogenesis inhibitors in the treatment of prostate cancer
Paul G. Kluetz et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
VEGF Inhibitors and Prostate Cancer Therapy
Jeanny Aragon-Ching et al.
Current Molecular Pharmacology (2010)
Vascular Endothelial Growth Factor
Napoleone Ferrara
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
The function of vascular endothelial growth factor
Bonnie J. Nieves et al.
BIOFACTORS (2009)
mTOR, cancer and transplantation
Edward K. Geissler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
All roads lead to mTOR - Integrating inflammation and tumor angiogenesis
Dung-Fang Lee et al.
CELL CYCLE (2007)
Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway
D. Barb et al.
ENDOCRINE-RELATED CANCER (2007)
Obesity and prostate cancer: Epidemiology and clinical implications
W. Cooper Buschemeyer et al.
EUROPEAN UROLOGY (2007)
Obesity and prostate cancer: A role for adipokines
Tina Mistry et al.
EUROPEAN UROLOGY (2007)
Vascular endothelial growth factor family of ligands and receptors: Review
Zaher K. Otrock et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
Role of vascular endothelial growth factor in prostate cancer
Nicolas Barry Delongchamps et al.
UROLOGY (2006)
Adiponectin: A novel adipokine linking adipocytes and vascular function
BJ Goldstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
T Yamauchi et al.
NATURE (2003)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Share Paper
